

Quality of life assessment and patient acceptability of intermittent versus continuous sex hormone suppression as treatment for locally advanced or metastatic prostatic cancer

Submission date 30/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/09/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 17/09/2012	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Timothy Philp

Contact details
Consultant Urologist
WXUHT
London
United Kingdom
E11 1NR

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0080056792

Study information

Scientific Title

Study objectives

This study will investigate patient acceptance, quality of life and survival/disease progression free interval in patients with locally advanced or metastatic prostate cancer in remission after six months treatment and disease control with androgen blockade.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Cancer: Prostate

Interventions

Intermittent vs continuous sex hormone suppression

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Patient acceptance, quality of life and survival/disease progression.

Secondary outcome measures

Not provided at time of registration

Overall study start date

31/12/1997

Completion date

31/12/2003

Eligibility

Key inclusion criteria

200 patients recruited from Urological Oncology Clinical who have had six months androgen blockade.

Participant type(s)

Patient

Age group

Not Specified

Sex

Male

Target number of participants

200

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

31/12/1997

Date of final enrolment

31/12/2003

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Consultant Urologist

London

United Kingdom

E11 1NR

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

+44 (0)20 7307 2622

dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

<http://www.dh.gov.uk/Home/fs/en>

Funder(s)

Funder type

Charity

Funder Name

Orchid Cancer Appeal (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2004		Yes	No